MX2019000582A - Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo. - Google Patents
Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo.Info
- Publication number
- MX2019000582A MX2019000582A MX2019000582A MX2019000582A MX2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- dapagliflozin
- crystal form
- method therefor
- dapagliflozin intermediate
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 4
- 229960003834 dapagliflozin Drugs 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describen una forma cristalina de un intermediario de la dapagliflozina y un método de preparación del mismo y se describen, específicamente, una forma cristalina del intermediario de la dapagliflozina ( 2S, 3R,4S, 5S, 6R)-2-( 4- cloro- 3-( 4- etoxibencil) fenil)-2- etoxi- 6-( metilhidroxil)tetrahidro- 2H-piran- 3, 4, 5- triol y un método de preparación del mismo. Las ventajas del mismo radican en que un intermediario puede ser purificado altamente para obtener una muestra con una pureza de 99.3% o más, en donde el mismo tiene un alcance importante para mejorar la calidad de la dapagliflozina y el proceso de preparación es simple y adecuado para la producción industrial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610587582.7A CN107641139A (zh) | 2016-07-22 | 2016-07-22 | 达格列净中间体的晶型及其制备方法 |
| PCT/CN2017/093833 WO2018014866A1 (zh) | 2016-07-22 | 2017-07-21 | 达格列净中间体的晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000582A true MX2019000582A (es) | 2019-04-01 |
| MX380815B MX380815B (es) | 2025-03-12 |
Family
ID=60992959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000582A MX380815B (es) | 2016-07-22 | 2017-07-21 | Forma cristalina de un intermediario de la dapagliflozina y método de preparación del mismo. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836786B2 (es) |
| EP (1) | EP3489250A4 (es) |
| JP (1) | JP2019521151A (es) |
| KR (1) | KR20190031485A (es) |
| CN (2) | CN107641139A (es) |
| BR (1) | BR112019000521A2 (es) |
| MX (1) | MX380815B (es) |
| WO (1) | WO2018014866A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020151672A1 (zh) * | 2019-01-23 | 2020-07-30 | 苏州科睿思制药有限公司 | 一种达格列净晶型及其制备方法和用途 |
| WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
| CN111748004A (zh) * | 2020-06-30 | 2020-10-09 | 药璞(上海)医药科技有限公司 | 一种高纯度达格列净中间体的晶型及其制备方法 |
| CN113979978A (zh) * | 2021-03-31 | 2022-01-28 | 浙江美诺华药物化学有限公司 | 一种达格列净的制备方法 |
| CN116813675B (zh) * | 2023-08-23 | 2023-11-24 | 北京远大九和药业有限公司 | 一种化合物晶型及其制备、组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL218714A (en) * | 2004-03-16 | 2013-02-28 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| US9193751B2 (en) * | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| CN104109179A (zh) * | 2013-04-16 | 2014-10-22 | 杭州华东医药集团生物工程研究所有限公司 | 一类c-芳基葡萄糖苷衍生物、制备方法及其用途 |
| EP3114115A4 (en) * | 2014-03-06 | 2017-08-23 | MSN Laboratories Private Limited | Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof |
| CN105481915A (zh) * | 2014-09-19 | 2016-04-13 | 北京万生药业有限责任公司 | 一种sglt-2抑制剂化合物的制备方法 |
-
2016
- 2016-07-22 CN CN201610587582.7A patent/CN107641139A/zh active Pending
-
2017
- 2017-07-21 JP JP2019501701A patent/JP2019521151A/ja active Pending
- 2017-07-21 CN CN201780033823.6A patent/CN109219611B/zh active Active
- 2017-07-21 EP EP17830500.9A patent/EP3489250A4/en not_active Withdrawn
- 2017-07-21 KR KR1020197001816A patent/KR20190031485A/ko not_active Withdrawn
- 2017-07-21 MX MX2019000582A patent/MX380815B/es unknown
- 2017-07-21 BR BR112019000521-8A patent/BR112019000521A2/pt not_active IP Right Cessation
- 2017-07-21 WO PCT/CN2017/093833 patent/WO2018014866A1/zh not_active Ceased
- 2017-07-21 US US16/317,636 patent/US10836786B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20190284220A1 (en) | 2019-09-19 |
| EP3489250A1 (en) | 2019-05-29 |
| WO2018014866A1 (zh) | 2018-01-25 |
| EP3489250A4 (en) | 2020-02-26 |
| CN107641139A (zh) | 2018-01-30 |
| JP2019521151A (ja) | 2019-07-25 |
| US10836786B2 (en) | 2020-11-17 |
| CN109219611B (zh) | 2022-03-29 |
| MX380815B (es) | 2025-03-12 |
| BR112019000521A2 (pt) | 2019-04-24 |
| CN109219611A (zh) | 2019-01-15 |
| KR20190031485A (ko) | 2019-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000582A (es) | Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo. | |
| EA201891657A1 (ru) | Интегрированный процесс ферментации и электролиза | |
| EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
| AR102049A1 (es) | Microorganismo que produce o-fosfoserina y un procedimiento para la producción de o-fosfoserina o l-cisteína por el uso del mismo | |
| MY199255A (en) | Method of producing high purity d-psicose | |
| MX2019011778A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| MX394386B (es) | Derivado de quinolina muy puro y metodo para su produccion. | |
| AU2015327117A8 (en) | Tellurate joining glass having processing temperatures less than or equal to 420 °C | |
| EA201992822A1 (ru) | Способ получения изолирующего материала или изолирующих продуктов для промышленности огнеупорных материалов, соответствующие изолирующие материалы и продукты, а также варианты применения | |
| EA201790794A1 (ru) | Способы разделения диастереоизомеров фосфата гемцитабина | |
| MX2021011401A (es) | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion. | |
| PE20171131A1 (es) | Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa) | |
| BR112017028322A2 (pt) | compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i | |
| EA201890771A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
| CL2021001511A1 (es) | Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma | |
| MY184725A (en) | Process for the purification of biomass hydrolysate | |
| EA201591013A1 (ru) | Оконное стекло с уплотнением по периметру и соответствующий способ его изготовления | |
| EA202090980A1 (ru) | Синтез антибактериальных аминогликозидных аналогов | |
| IT201800007229A1 (it) | Processo microbiologico per la produzione di pane d’api | |
| EA202191502A1 (ru) | Способ получения апиксабана | |
| MX2021008301A (es) | Proceso de purificacion de ficocianinas. | |
| CO2017006157A2 (es) | Método de manufactura de proteína | |
| EA201990345A1 (ru) | Постоянно поляризованный гидроксиапатит, способ его получения и его применения | |
| CL2018002149A1 (es) | Proceso. | |
| AR104145A1 (es) | Método de producción de epirrubicina, intermediario y sal farmacéutica |